Mirum Pharmaceuticals, Inc. (MIRM)

NASDAQ: MIRM · IEX Real-Time Price · USD
19.42
-0.04 (-0.21%)
Jul 1, 2022 1:15 PM EDT - Market open

Company Description

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.

The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.

It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals Logo
Country United States
Founded 2018
IPO Date Jul 18, 2019
Industry Biotechnology
Sector Health Care
Employees 144

Contact Details

Address:
950 Tower Lane
Foster City, CA 94404
United States
Phone 650 667 4085
Website mirumpharma.com

Stock Details

Ticker Symbol MIRM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
IPO Price $15.00
CIK Code 1759425
CUSIP Number 604749101
ISIN Number US6047491013
SIC Code 2834

Key Executives

Name Position
Christopher Peetz President, Chief Executive Officer and Director
Dr. Ian Clements Chief Financial Officer
Peter Radovich M.B.A., Ph.D. Chief Operating Officer
Paul K. Ross Chief Compliance Officer
Erin Campany Senior Vice President of Human Resources
Dr. Pamela Vig Ph.D. Head of Research & Development
Lara Longpre MBA, MSC Chief Development Officer
Vinita P. Kumar Senior vice President of Quality
Saira Gonsalves Ramasastry M.S. Managing Partner of Life Sciences Advisory, LLC

Latest SEC Filings

Date Type Title
Jun 10, 2022 EFFECT Notice of Effectiveness
Jun 8, 2022 4 Statement of changes in beneficial ownership of securities
Jun 7, 2022 3 Initial statement of beneficial ownership of securities
Jun 6, 2022 4 Statement of changes in beneficial ownership of securities
Jun 6, 2022 4 Statement of changes in beneficial ownership of securities
Jun 6, 2022 4 Statement of changes in beneficial ownership of securities
Jun 6, 2022 4 Statement of changes in beneficial ownership of securities
Jun 6, 2022 4 Statement of changes in beneficial ownership of securities
Jun 6, 2022 4 Statement of changes in beneficial ownership of securities
Jun 6, 2022 4 Statement of changes in beneficial ownership of securities